NEW YORK (GenomeWeb News) – The genomic information services company BioServe has reached an agreement with The Fairbanks Institute for Healthy Communities to co-market a biorepository recently started by the non-profit institute, BioServe said today.
Under the agreement, BioServe will co-market biological samples from INbank, which was developed from the Indiana Health Study — a longitudinal cohort study of the Central Indiana population that was sponsored by the Indianapolis-based Fairbanks Institute. The biorepository connects samples from the health study to information available in patient histories and clinical outcomes data for use in research and development of new diagnostics, preventions, and treatments for disease.
Currently, the Fairbanks Institute has longitudinal studies underway focusing on coronary artery disease and type 2 diabetes.
The updated clinical information on the health study's participants comes from the Indiana Network for Patient Care (INPC), which is an electronic medical record network for supporting patient care, research, and quality as well as improvements in public health. The INPC's patient system includes clinical data from more than 40 hospitals, data from payors, prescription data from benefit managers, pharmacies, and public health data.
BioServe's "expertise in biological samples will help to maximize the scientific impact of INbank on the development of new diagnostics and therapeutics for chronic diseases," Fairbanks Institute President and CEO Cynthia Helphingstine said in a statement.
BioServe, which has headquarters in Beltsville, Md., and in India, provides a library of 600,000 human DNA, tissue, and serum samples, as well as relevant clinical and demographic data from 120,000 patients from four continents.